SR9009 10mg is a Rev-Erb agonist oral tablet formulation supplied in a 50 tablet pack. Manufactured for consistent potency, stability, and research applications.
Format50 Tablets
Concentration10mg
Pay with Interac e-Transfer or Crypto
HPLC verified. COA on file for this batch
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
SR9009, commonly known as Stenabolic, is a synthetic Rev ErbA agonist and while frequently grouped alongside SARMs in research product categorization, it is mechanistically unrelated to androgen receptor activity entirely, operating instead through nuclear receptor modulation of the circadian clock and metabolic gene expression pathways. F40 Biotech’s formulation delivers 10mg per tablet in a 50 count format, consistent with the concentration most commonly referenced in Rev ErbA agonist preclinical research literature.
Rev ErbA is a nuclear receptor that functions as a core component of the molecular circadian clock, repressing the transcription of genes involved in lipid and glucose metabolism, mitochondrial biogenesis, and inflammatory pathways on a circadian rhythm dependent schedule. SR9009’s agonist activity at Rev ErbA produces effects that mimic and amplify this natural repressive transcriptional activity. Research has documented its influence on increasing mitochondrial number and oxidative metabolism in skeletal muscle, reducing adipogenesis, and modulating macrophage inflammatory activity in preclinical models. This mechanism is entirely distinct from every SARM, anabolic steroid, and growth hormone secretagogue in CSD’s range; SR9009 does not interact with the androgen receptor, estrogen receptor, or growth hormone axis in any capacity, making it a frequently misunderstood compound that is more accurately classified alongside metabolic research compounds like 5-Amino-1MQ and SLU-PP-332 than alongside true SARMs.
SR9009’s research profile is most extensively documented in metabolic and circadian biology literature, studies examining its effects on mitochondrial biogenesis, oxidative metabolism, and the circadian regulation of lipid and glucose homeostasis represent the primary preclinical research base for this compound. Its mechanism of nuclear receptor mediated transcriptional repression distinguishes it from receptor binding hormone analogues, positioning it as a unique tool for research examining the intersection of circadian biology and metabolic regulation independent of the androgen or growth hormone signaling pathways studied elsewhere in CSD’s range.
F40 Biotech formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s sourcing standards apply uniformly across all manufacturers we carry, and F40 Biotech’s SR9009 meets those standards consistently. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Store in a cool, dry place away from direct light and heat. Intended for research purposes only.
Commonly researched alongside SLU-PP-332 and 5-Amino-1MQ in comparative metabolic and mitochondrial regulation studies. Browse CSD’s full SARM and metabolic research range for complete sourcing.
SR9009 (Stenabolic) is a synthetic REV-ERBα agonist; a compound that activates REV-ERB nuclear receptors involved in the regulation of circadian rhythm, metabolism, inflammation, and mitochondrial biogenesis. Despite being frequently categorized alongside SARMs, SR9009 is not an androgen receptor modulator, it operates through an entirely different mechanism. It is researched for its dramatic effects on endurance capacity, fatty acid oxidation, glucose metabolism, and mitochondrial density. Animal research demonstrates significant improvements in running endurance, reduction in fat mass, improved lipid profiles, and reduced inflammation. SR9009 does not suppress the HPG axis and requires no PCT. Making it one of the most studied performance research compounds without hormonal side effects.
SR9009 has a very short half-life of approximately 4–5 hours, one of the shortest half-lives of any commonly researched performance compound. This requires multiple daily administrations to maintain active REV-ERBα engagement throughout the day. Most research protocols administer SR9009 three to four times daily at equal intervals for example 10mg upon waking, 10mg at midday, 10mg in the afternoon, and 10mg in the early evening for a 40mg total daily dose. This frequent dosing schedule is the primary practical limitation of SR9009 research compared to once daily compounds. The 50 tablet pack at 10mg provides 500mg total; sufficient for 12–25 days of research at 20–40mg daily depending on dose.
SR9009's REV-ERBα agonism produces several well documented metabolic and endurance effects in animal research. Mitochondrial biogenesis; increasing the number and efficiency of mitochondria in muscle tissue; directly enhances oxidative capacity and aerobic endurance. Increased fatty acid oxidation shifts substrate utilization toward fat burning at a given exercise intensity. Improved glucose metabolism enhances insulin sensitivity and glycogen utilization efficiency. Reduced inflammatory cytokine production supports faster recovery between training sessions. These combined effects produce dramatic endurance improvements in animal models, making SR9009 one of the most studied compounds for aerobic capacity and metabolic efficiency research.
No! SR9009 does not interact with androgen receptors or the HPG axis in any meaningful way. It produces no testosterone suppression, no LH or FSH reduction, and requires no post cycle therapy. This makes it one of the most practically accessible performance research compounds. It can be run as a standalone or stacked with other compounds without adding hormonal management complexity to the research protocol. Blood work monitoring for lipid profiles is still recommended given its significant effects on lipid metabolism.
Yes! This batch has been independently HPLC tested by an accredited third party laboratory confirming concentration accuracy at 10mg per tablet and compound identity as SR9009 (Stenabolic). A certificate of analysis is available.
